Which entities should sponsor-specific essential documents be retained for in conformance with regulatory requirements?

• A. The country(ies) where the product is approved and/or where approvals are sought.
• B. The sponsor's home country.
• C. Any country.
• D. The country where the product is approved.

Answer: (D)

Document retention for the sponsor’s essential records is kept in the jurisdiction where the product is approved because that is the authority that will oversee the product and require access to records for inspections and regulatory compliance. Storing the documents in the country of approval ensures regulators can review the trial records as part of ongoing pharmacovigilance, inspections, and potential submissions related to that product. Keeping them only in the sponsor’s home country may not satisfy the retention and accessibility requirements of the authorities in the country where the product is marketed. Likewise, choosing any country or only where approvals are being sought can create gaps in regulatory access. Therefore, aligning retention with the country of product approval best meets regulatory expectations and supports audit readiness.